HIGHLIGHTS
- What: The studies analyzed in this review provide some evidence that each targeted drug and ICIs has unique immunomodulatory effects, and that the target population benefiting from these treatments may differ significantly.
- Who: HCC and collaborators from the University of California, San Diego, United States have published the research work: The current status and future of targeted-immune combination for hepatocellular carcinoma, in the Journal: (JOURNAL)
- Future: Effectively utilizing the synergistic effect of different anti-tumor mechanisms will be the focus of future research and is expected to transform the current landscape of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.